Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa with concurrent long-course radiotherapy and XELOX for MSS locally advanced rectal cancer
ChiCTR2600135535Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of retlirafusp alfa, capecitabine and oxaliplatin in rectal adenocarcinoma, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfacapecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600135535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135535.